Skip to content

Wearable Biosensors

Wearable biosensors monitor vital signs, sweat analytes, and other indicators of patient wellbeing, including heartbeat, blood pressure, motion, and body temperature. These devices, along with electronic skin patches, collect critical data that can be analyzed to support a more proactive approach to healthcare. By partnering with Resonetics®, MedTech innovators leverage this technology in skin patches, body sensors, cardiac monitors, continuous glucose monitors (CGM), and more. As an ISO 13485:2016-certified manufacturer, we provide integrated production support from design to full-scale production.

Electronic Skin Patches

Electronic skin patches are thin and flexible products that attach to the user’s skin with biocompatible adhesives and have integrated sensors, processors, and communication elements. We specialize in manufacturing these products with our automated capabilities in roll-to-roll laser processing, die cutting, circuit fabrication, and stack lamination. Electronic skin patches can be used for many different inpatient and at-home applications, including, but not limited to:

  • Motion and position sensing
  • Analyte sensing
  • Sweat monitoring
  • Vital signs
  • Temperature
  • Drug and cosmetic delivery
  • Newborn monitoring
  • Smart wound care
  • General sensing
Knowledge Center
news

Resonetics® Acquires Eden Holdings, Adding Injection Molding to its Capabilities

brochure

COMING SOON: Contego® 100 mAh Battery

articles

The Power of an Integrated Nitinol Supply Chain

articles

Resonetics Celebrates 35 Years of Consistent Nitinol Melting and Processing

articles

The Benefits of Nitinol for Orthopedic Devices: Q&A with Eric Veit

whitepapers

Nitinol Post-Shape-Setting TTT & TTS Properties

news

Resonetics® Invests in Nitinol Gun Drilling Capabilities Through Purchase of Assets from Medical Component Specialists

articles

Impact of Nitinol in Medical Device Manufacturing: Q&A with Scott Robertson

articles

Ensuring Stability in the Nitinol Supply Chain: Q&A with Rich LaFond

0